Consolidation 2nd(3weeks)

Phase 2Small molecule

Consolidation 2nd(3weeks) is one of 4 small molecule programs targeting Acute Lymphoid Leukemia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Lymphoid LeukemiaRecruiting

Acute Lymphoid LeukemiaPhase 2

Recruiting

Competition

Competitive Landscape

9 competitors in Acute Lymphoid Leukemia

#DrugCompanyPhaseTrials

Besponsa

WWyeth-Lederle Vaccines

Phase 2

1 2

Consolidation 2nd(3weeks)

HHo Joon Im

Phase 2

1 3

Maintenance

SSWOG Cancer Research Network

Phase 2

1 4

Standard Therapeutic DLI

UUniversity of Arizona

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2032

Phase 2Recruiting

Acute Lymphoid Leukemia

NCT05827549

Clinical

Trials by Indication[1]

Acute Lymphoid Leukemia1 trial

Evaluation of Treatment Efficacy According to Risk Group in Relapsed Childhood Acute Lymphoblastic Leukemia

Recruiting·HHo Joon Im·Phase 2·NCT05827549·90 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Consolidation 2nd(3weeks). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Consolidation 2nd(3weeks) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Consolidation 2nd(3weeks). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ho Joon Im company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: HHo Joon Im

Consolidation 2nd(3weeks)

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2032

Trials by Indication[1]

Acute Lymphoid Leukemia1 trial

References

Drug Info

Quick Facts

Related News